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Abstract
Background
Multidrug resistant tuberculosis (MDR-TB), is an emerging public health problem in sub-
Saharan Africa (SSA). This study aims to determine the trends in prevalence of MDR-TB
among new TB cases in sub-Saharan Africa over two decades.
Methods
We searched electronic data bases and accessed all prevalence studies of MDR-TB within
SSA between 2007 and 2017. We determined pooled prevalence estimates using random
effects models and determined trends using meta-regression.
Results
Results: We identified 915 studies satisfying inclusion criteria. Cumulatively, studies
reported on MDR-TB culture of 34,652 persons. The pooled prevalence of MDR-TB in new
cases was 2.1% (95% CI; 1.7–2.5%). There was a non-significant decline in prevalence by
0.12% per year.
Conclusion
We found a low prevalence estimate of MDR-TB, and a slight temporal decline over the
study period. There is a need for continuous MDR-TB surveillance among patients with TB.
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Introduction
Multi drug resistant tuberculosis (MDR-TB) is a global public health challenge, especially in
sub-Saharan Africa (SSA), where it adds to the burden of other communicable and non-
communicable diseases bedeviling the region. In 2015 WHO estimated 480,000 new cases of
MDR-TB worldwide. An additional 100,000 cases were rifampicin-resistant TB (RR-TB), mak-
ing them eligible for MDR-TB treatment.[1] Cases of MDR-TB continue to rise—whereas, in
2014, MDR-TB constituted 3.3% of new Tuberculosis (TB) cases, in 2015 an estimated 3.9% of
new and 21% of previously treated TB cases were found to be (MDR/RR-TB). [2]
The emergence of MDR-TB is linked to weak TB control programs and sub-optimal TB
case management.[3]This realization is more pronounced in SSA, due to its limited resources
and dearth of trained TB health work force[4]. Indeed, by 2016 only 18 out of the 46 SSA coun-
tries reported ever conducting a national MDR-TB survey,[1] a major constraint to proper
planning and to achieving the End TB Strategy targets.[5, 6]
In view of the paucity of national MDR-TB survey in SSA a number of studies have
attempted to estimate the burden of MDR-TB in SSA. Lukoye in The Netherlands, [7] found a
pooled MDR-TB prevalence estimate of 1.5% (95% CI 1.0–2.3), while Berhan in Ethiopia,
reported a five-fold increased risk of MDR-TB among previously treated tuberculosis (TB)
cases compared to new cases.[8] Available literature on prevalence of MDR-TB in SSA depicts
remarkable within and between country differences.[7, 8]
Considering the significant within and between country variability in reported MDR-TB
prevalence in SSA, this review aims to provide a comprehensive and up-to-date evaluation of
the burden and trend of the MDR-TB among new cases in SSA. Findings from this work can
inform intervention strategies and future MDR-TB monitoring.
Materials and methods
Data search
Three of the authors independently searched for literature related to prevalence of MDR-TB in
selected bibliographic databases, namely PubMed/Medline, Institute of Science Information
(ISI), Google Scholar, African Journals Online (AJOL), BIOLINE Cochrane, HINARI, Embase,
and Scopus. The search was limited to 1st January 1997 to 31st May 2017, with no language
restriction. The reference list of retrieved papers was further searched to identify additional
relevant literature. We contacted authors for unpublished literature and publications with
inconclusive reporting. Subject specialists were further contacted for unpublished write ups.
The search strategy combined keywords and medical subject headings (MeSH). The follow-
ing key search terms were used: “prevalence” or “burden”; “Mycobacterium tuberculosis” or
“tuberculosis”; “anti-TB drug susceptibility” or “anti-TB drug resistance”; “Resistant TB” or
“MDRTB” and “Africa” or “Sub-Saharan Africa”. These string were further attached to names
of SSA countries. Details of the Pubmed search strategy (one of the databases) are depicted in
S1 Table.
Inclusion and exclusion criteria
Data on MDR in new TB cases from studies reporting prevalence of MDR-TB among new TB
cases and data on MDR TB in new cases from studies with disaggregated data on new and
retreatment cases were included in the final analysis. We used adjudication to resolve discrep-
ancies on articles to be included.
We excluded from the analysis case reports case series, studies without primary data, com-
mentaries, literature reviews, studies adjudged to have poor quality based on NIH criteria,[9]
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studies presenting data before 1997, studies with data unrelated to MDR-TB, studies without
adequate data, studies not reporting the culture or DST method, studies not reporting the sam-
pling method, studies reporting only data on retreatment cases, and studies reporting new and
retreatment cases without disaggregation.
Data extraction
The following information were extracted from the eligible studies: first author’s name; year of
publication; country of study; study design; study description; study setting; culture and DST
methods; numeric count of MDR-TB cases; numeric count of new TB cases screened; age
group; HIV prevalence in the study (HIV prevalence at national level for each country of inter-
est was collected from the UNAIDS Report 2017); and type of resistance tested. We coded data
based on authors name, study country, and year of study. Multiple Coder agreement was
assessed using Cohen’s kappa.
Operational definitions
WHO defines resistance among new cases as resistance to one or more anti-tuberculosis drugs
in patients that have never been treated for TB, while “MDR-TB” implies that TB is resistant to
at least rifampicin and isoniazid. This is to distinguish it from MDR-TB in old cases which
would refer to occurrence of MDR in patients with prior TB treatment. We defined SSA sub-
regions as follows: Eastern sub-region; West Africa sub-region; Southern sub-region and Cen-
tral Africa sub-region. Identification of TB was done using Lo¨wenstein-Jensen BACTEC, and
GeneXpert MTB/RIF assay (Xpert1 MTB/RIF assay (Cepheid, Sunnyvale, CA, USA). The
drug sensitivity test (DST) methods used were the proportion method, the absolute concentra-
tion method GeneXpert MTB/RIF assay, and BACTEC method. While some studies used LJ,
BACTEC MGIT 960 system, or BACTEC 460 TB radiometric as a standalone test, others used
a mix of diagnostic methods.
Quality of included studies
Two of the authors independently assessed quality of included studies using the NIH Quality
Assessment Tool for Observational Cohort and Cross-Sectional Studies.[9] Studies were
assessed with questions appropriate to their study design. We graded quality as good (G) if rat-
ing was at least 70%, fair (F) if at least 50%, and poor (P) if less than 50%.
Statistical analyses
The primary outcome measure was prevalence of MDR-TB. Standard error of prevalence was
estimated using binomial probability distribution. Overall and sub-group pooled effect size
was estimated using random effects model with DerSimonian-Laird method by calculating the
pooled prevalence estimate and confidence interval, based on the weighted least square
(weighting was given by the reciprocal sum of between and within study variances). Between-
studies heterogeneity was evaluated using Cochran’s Q test. A priori, we defined low, medium
and high heterogeneity as a Cochran’s Q of 25%, 50%, and 75%, respectively. To determine
potential confounders and prevalence trend, meta-regression analysis was done. We appraised
publication bias by funnel plot, Begg’s rank correlation methods and Egger’s weighted regres-
sion test. Prevalence derived from included studies were depicted on funnel plot by diamond
points, while augmented data prevalence obtained using the trim and fill method are repre-
sented by a diamond symbol within a square. All analyses were performed using STATA soft-
ware (version 11). We adopted 0.05 as significant level for the Cochran’s test. We ran a
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sensitivity analysis to assess the effect of sample size on the aggregate prevalence. The null
hypothesis of this study assumes that the all the studies have the same prevalence in the various
populations studied.
Results
Characteristics of included studies
A total of 915 citations were found, out of which 51 articles were included in the qualitative
review.[10–60], and 49 articles that met the inclusion criteria were included in the meta-
analysis. (two were finally excluded on account of using Gene Xpert alone for diagnosing
MDR TB),Fig 1. These comprised of 35 cross-sectional studies, ten prospective cohort studies,
and four retrospective cohort studies. Characteristics of included studies are summarized in
(S3 Table). We used PRISMA and MOOSE checklist for assessment of meta-analysis guideline
compliance(S4 and S5 Tables).
Quality assessment
Based on the 10 quality domains assessed, most of the studies satisfied at least six of the quality
benchmarks. The most common quality benchmark failed by the studies were: inadequate
sample size, sample size justification, power description, or variance and effect estimates pro-
vided. While all included studies had a score of at least 50%, 32(65%) had a score of at least
70% Details of grading procedure is presented in S2 Table.
Pooled prevalence of MDR TB among new TB patients
The meta-analysis derived a pooled MDR-TB prevalence of 2.0% (95% CI; 1.7–2.4%) for new
cases of TB in SSA. [Fig 2] The identified number of new MDR-TB cases was based on culture
of samples from 34,056 individuals, spanning 20 years (1997–2017).
Table 1 shows the subgroup analyses for the prevalence of MDR-TB in new TB cases by
study design, region, and type of survey and study year. We found a wide disparity in the prev-
alence of evaluated characteristics.
The prevalence of MDR-TB was highest in retrospective studies with a prevalence of 4.1%
(95% CI: 1.6–6.6) and lowest in prospective studies 1.4(95% CI: 0.6–2.10). [Fig 3] Pooled prev-
alence of MDR-TB in national surveys was 1.5% (95% CI:1.0–2.0) and 2.5% (95 CI: 1.9–3.2) in
sub national surveys. When assessed by region, prevalence varied from 3.1% (95% CI: 2.1–4.2)
in the Southern African region to1.7% (95% CI: 1.1–2.2) in Eastern Africa. Table 1
When sensitivity analysis was performed by study year the prevalence of MDR-TB ranged
from 10.2% (95% CI: 2.3–22.7) in studies done in 1997, to 0.8% (95% CI: 0.1–1.5) in studies
done in 2006. [Table 1] Studies done in 2008 and 2010; the years with highest number of
reported studies (each seven) had a pooled prevalence of 1.7% (95% CI0.9–2.5) and 1.5% (95%
CI: 0.6–2.3) respectively. [Table 1]
We assessed evidence of trend in prevalence of MDR-TB in new TB cases using meta-
regression. There was a non-significant decline in the prevalence of MDR-TB, at a rate of
0.18% per year (p value = 0.07). [Fig 4] Study year, region, population, age, or method of
screening were not found to be significant confounders of MDR-TB prevalence estimates.
Table 2
We found evidence of publication bias using Egger’s and Begg’s test statistics (p value = 0.001
for both tests). The funnel plot demonstrated evidence of asymmetry. [Fig 5].
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Fig 1. PRISMA flow diagram showing study screening and selection procedure.
https://doi.org/10.1371/journal.pone.0185105.g001
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Discussion
With a pooled prevalence of 2.1%, we have demonstrated a low prevalence of MDR-TB in new
cases of TB in SSA. We have also shown evidence of a declining trend in the prevalence of
MDR-TB in new TB cases over a period of 20 years.). If it is assumed that Africa had a TB inci-
dence of 2,720/100,000 population in 2015,[1] then we would be projecting an MDR-TB bur-
den in new cases of 54/100,000 population, with uncertainty interval of (47–62)/100,000
population. With a review spanning 2007–2017, to our knowledge this study is the most recent
extensive review of the burden of MDR-TB in new cases in SSA. It is also the first study, to our
knowledge, to assess the trend in the prevalence of MDR-TB in SSA using meta-analytical
methods.
Our findings are consistent with WHO estimates of MDR-TB in new cases in Africa of
1.9%, (95% CI 0.6–3.3).[3] Similarly, an earlier meta-analysis (2013) reported a pooled preva-
lence of 1.5% (95% CI 1.0–2.3).[7] A recent MDR-TB survey in three SSA countries also dem-
onstrated a similar low prevalence of MDR-TB in new cases (prevalence range: 0.6–2.0).[61]
Fig 2. Forest plot showing pooled and individual weighted prevalence of included studies. ES: effect size, CI: confidence interval.
https://doi.org/10.1371/journal.pone.0185105.g002
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Whereas, we found a non-significant declining trend in the prevalence of MDR-TB in new
cases, Xiao-chun and Mukinda found rising trend in China and South Africa respectively[62,
63] However, our study modelled a composite measure of MDR-TB from different countries,
whereas, these studies assessed single country trends. These differences between our findings
and others buttress the need for continuous MDR-TB surveillance as a necessary tool for effec-
tive TB control. Drug resistance surveillance allows tracking of ongoing resistance transmis-
sion, and creates an enabling environment for planning.[3] Continuous surveillance of
MDR-TB would not only assess epidemiological trends, but also allow for timely determina-
tion and response to MDR-TB outbreaks. Further, continuous surveillance helps to track the
effectiveness of national and global TB prevention and control interventions, and allows for
optimum forecasting of patient treatment needs.[64]
We noted disparity in pooled prevalence based on study design. The highest prevalence lev-
els were observed in retrospective cohort studies, while the lowest prevalence values were
observed in prospective studies. Similarly, pooled prevalence levels of national surveys were
lower than values reported from sub-national surveys. Almost all national surveys included in
the meta-analysis had cross- sectional study design, with their pooled prevalence being closer
to the overall pooled prevalence. This finding may reflect the good rigor involved in designing
national surveys.
The pooled prevalence of MDR-TB in new cases was highest in studies from Southern
Africa and lowest in Eastern African studies, while the pooled prevalence for West and Central
African sub-regions were mid-way. Although there is high heterogeneity within and between
Table 1. Disaggregated prevalence of MDR-TB by study attributes and their measure of heterogeneity.
Category stratified by Sub-group Number of studies reviewed Prevalence of MDR-TB % (95%CI) Heterogeneity test
I2% p value
Study design Prospective 10 1.4(0.6–2.1) 82.2 0.001
Retrospective 4 4.1(1.6–6.6) 89.3 0.001
Cross-sectional 35 2.2(1.7–2.7) 88.4 0.001
Region Western 12 1.9(1.2–2.6) 54.4 0.001
Eastern 20 1.7(1.1–2.2) 87.2 0.001
Central 8 2.1(1.1–3.0) 75.2 0.001
Southern 9 3.1(2.1–4.2) 96.2 0.001
Type of survey National survey 13 1.5(1.0–2.0) 93.3 0.001
Sub-national survey 36 2.5(1.9–3.2) 86.0 0.001
Year of study 1997 2 10.2(2.3–22.7) 94.8 0.001
1999 4 3.6(0.5–6.7) 94.0 0.001
2001 2 5.2(4.4–14.8) 98.5 0.001
2002 5 1.2(0.1–2.6) 61.1 0.001
2004 2 1.3(0.1–2.6) 75.5 0.001
2005 2 2.6(2.0–3.1) 0.0 0.001
2006 3 0.8(0.1–1.5) 60.1 0.001
2007 4 2.9(0.2–5.6) 94.6 0.001
2008 7 1.7(0.9–2.5) 49.3 0.001
2009 5 2.6(0.9–4.4) 82.8 0.001
2010 7 1.5(0.6–2.3) 67.6 0.001
2011 3 2.2(0.1–4.5) 91.8 0.001
2012 2 1.6(2.0–5.2) 73.1 0.001
2014 1 2.3(0.8–5.4) 0.0 0.001
https://doi.org/10.1371/journal.pone.0185105.t001
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Southern African countries, it is not surprising to find relatively high primary MDR-TB resis-
tance there, because of the substantial contribution of South Africa to the global and regional
burden of TB. Our findings are consistent with an earlier WHO report of relatively high preva-
lence of MDR-TB in new cases in Southern Africa.[3] Southern Africa has one of the highest
regional global prevalence in HIV. Although conclusive evidence of the association between
HIV and risk of developing MDR-TB is lacking, it is plausible that high HIV burden could be
contributing to the observed MDR-TB burden in this sub-region.[7, 8]
Although the pooled prevalence trend obtained in this study using regression
modeling may suggest a declining trend in MDR-TB, sensitivity analysis on year of study was
heterogeneous, with no clear discernable pattern. This finding could be explained by the dispa-
rate study design, varying study population sizes, and settings in which these studies were
conducted.
Fig 3. Forest plot showing pooled MDR TB prevalence in new TB cases stratified by study design of included studies. ES: effect size, CI:
confidence interval.
https://doi.org/10.1371/journal.pone.0185105.g003
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Fig 4. Meta-regression plot showing sub-Saharan African (S SA) trend in MDR-TB prevalence in new
cases over two decades. P: MDR TB prevalence in new cases, circle size proportionate to size of studied
population in each year.
https://doi.org/10.1371/journal.pone.0185105.g004
Table 2. Meta-regression: Association between pooled prevalence of new MDR TB cases and study characteristics.
CHARACTERISTICS ¶ Univariate coefficient 95% CI: () P value Adjusted coefficient P value
Year of study -0.0018 (-.0037 .00015) 0.070
Study design
Cross sectional Ref -
Prospective -0.0056 (-0.026 0.016) 0.598 -
Retrospective 0.016 (-0.0149 .0482) 0.296
Region, -
Central Africa Ref -
East Africa -0.0023 (-0.026–0.022) 0.850 -
Southern Africa 0.016 (-0.012–0.043) 0.259 -
West Africa .0019786 (-0.025–0.029) 0.882 -
Population Collinearity - -
Age, Collinearity - -
Method of screening -
BACTEC 460 Ref -
BACTEC 960 .00233(-0.020–0.024) 0.836 -
LJ .00906 (-0.050 0.068) 0.762 -
HIV prevalence in study -0.0001 (-0.0006 .0005) 0.696 -
¶The regression coefficients are the estimated increase in the MDR TB prevalence per unit increase in the study characteristics
https://doi.org/10.1371/journal.pone.0185105.t002
MDR-TB trend in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0185105 September 25, 2017 9 / 15
Many SSA countries have adopted WHO recommendation of using Xpert MTB/RIF assay
in screening for MDR-TB in new cases. However its utility when used as a standalone might
be limited, considering its relatively low positive predictive value in populations with low bur-
den of MDR-TB. In view of the cost to individuals and health system of unnecessarily treating
MDR-TB in SSA, we advocate augmenting Xpert MTB/RIF assay with drug sensitivity testing
DST.[65]
Our finding of significant publication bias may be a reflection of wide heterogeneity in
reported prevalence of MDR-TB and of potential gaps in data from unreported prevalence in
certain sub populations. We have attempted to account for missing data points using the fitted
data from iteration based on the “trim and fit methods” of assessing publication bias. Other
possible reasons for this finding include: differences in study sample sizes, TB culture methods,
and variation in study rigor. Our finding may also reflect temporal variability in prevailing risk
for MDR-TB among study populations. We have tried to include only high quality with rating
of at least 50%.[9]
Our study had some of limitations. Not all countries in SSA had reported MDR-TB national
surveys, as such we had to rely on prevalence assessment in sub-populations. Nevertheless,
these were considered fairly representative. We equally had to exclude some studies because
they did not clearly delineate data into new or relapse cases.
Conclusion
This study shows a low MDR-TB prevalence in new cases, and declining prevalence of
MDR-TB over the two decades covered by this study. Perhaps this finding may not necessarily
suggest a low MDR-TB prevalence and prevalence decline, but rather limitation in the number
of reports of national MDR-TB surveys in SSA. This study depicts gaps in documentation of
MDR-TB cases in several SSA countries. In countries with available data, documentation is
Fig 5. Trim and filled funnel plot depicted study derived and data augmented prevalence of MDR-TB
in new cases for SSA. Theta: the effect (prevalence) estimate, SE: standard error; diamond shapes
represent study derived prevalence; diamond within square represent data augmented prevalence.
https://doi.org/10.1371/journal.pone.0185105.g005
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often limited to sub populations, without the necessary national representativeness of a
national survey. While data from national MDR-TB surveys are rewarding as interim mea-
sures, a truly robust understanding would be better achieved if MDR-TB assessment is inte-
grated into routine TB care to achieve continuous drug resistance surveillance. A better
understanding of epidemiological trends in drug resistance at the global and national levels
can be achieved through repeated surveys and, ultimately, by establishing proper MDR-TB
surveillance systems. We advocate for rigorous and representative MDR-TB surveillance sys-
tems that would generate data to guide the development and prioritization of MDR-TB control
policies within and across national borders.
Supporting information
S1 Table. Search strategy used for one of the databases (PubMed). MeSH: medical sub-
heading.
(DOCX)
S2 Table. Details of quality rating for included studies. Yes: satisfies criteria, No doesn’t sat-
isfy criteria, G: good score ( 70%), F: fair score (50%).
(DOCX)
S3 Table. Details of included study characteristics. LJ: Lo¨wenstein-Jensen, HAIN: Hain
assay, Xpert: Xpert1 MTB/RIF assay, MIGT: Mycobacterial growth indicator tube.
(DOCX)
S4 Table. PRISMA checklist of the systematic review.
(DOC)
S5 Table. MOOSE checklist for observational studies.
(DOC)
Acknowledgments
We wish to acknowledge the Vanderbilt Institute for Global Health, for Training on Research
Ethics.
Author Contributions
Conceptualization: Baba Maiyaki Musa.
Data curation: Baba Maiyaki Musa.
Formal analysis: Baba Maiyaki Musa.
Funding acquisition: Baba Maiyaki Musa.
Investigation: Baba Maiyaki Musa.
Methodology: Baba Maiyaki Musa.
Project administration: Baba Maiyaki Musa.
Resources: Baba Maiyaki Musa.
Software: Baba Maiyaki Musa.
Supervision: Baba Maiyaki Musa.
Validation: Baba Maiyaki Musa.
MDR-TB trend in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0185105 September 25, 2017 11 / 15
Visualization: Baba Maiyaki Musa.
Writing – original draft: Baba Maiyaki Musa, Aishatu L. Adamu, Najibah A. Galadanci,
Bashir Zubayr, Chisom N. Odoh, Muktar H. Aliyu.
Writing – review & editing: Baba Maiyaki Musa, Aishatu L. Adamu, Najibah A. Galadanci,
Bashir Zubayr, Chisom N. Odoh, Muktar H. Aliyu.
References
1. WHO | Global tuberculosis report 2016. In: WHO. http://www.who.int/tb/publications/global_report/en/.
Accessed 13 May 2017
2. WHO | Tuberculosis. In: WHO. http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 1 Apr
2017
3. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. (2012) Surveillance of anti-
tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ
90:111–119D https://doi.org/10.2471/BLT.11.092585 PMID: 22423162
4. Coker RJ (2004) Review: multidrug-resistant tuberculosis: public health challenges. Trop Med Int
Health 9:25–40 PMID: 14728604
5. WHO | WHO End TB Strategy. In: WHO. http://www.who.int/tb/post2015_strategy/en/. Accessed 13
May 2017
6. Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O’Grady J, et al. (2010) Review of multidrug-resis-
tant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop
Med Int Health 15:1052–1066 https://doi.org/10.1111/j.1365-3156.2010.02581.x PMID: 20545927
7. Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FGJ, Joloba M, et al. (2015) Variation and
risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.
BMC Public Health 15:291 https://doi.org/10.1186/s12889-015-1614-8 PMID: 25880829
8. Berhan A, Berhan Y, Yizengaw D (2013) A Meta-Analysis of Drug Resistant Tuberculosis in Sub-Saha-
ran Africa: How Strongly Associated with Previous Treatment and HIV Co-Infection? Ethiop J Health
Sci 23:271–282 PMID: 24307827
9. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies—NHLBI, NIH. https://
www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort.
Accessed 28 May 2017
10. Kuaban C, Bercion R, Noeske J, Cunin P, Nkamsse P, Ngo Niobe S (2000) Anti-tuberculosis drug resis-
tance in the West Province of Cameroon. Int J Tuberc Lung Dis 4:356–360 PMID: 10777086
11. Anastasis D, Pillai G, Rambiritch V, Abdool Karim SS (1997) A retrospective study of human immunode-
ficiency virus infection and drug-resistant tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis
1:220–224 PMID: 9432367
12. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E (1999) Low levels of drug
resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in
Botswana. Int J Tuberc Lung Dis 3:4–11 PMID: 10094163
13. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P (1999) Human immunodeficiency virus and
the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir
Crit Care Med 159:733–740 https://doi.org/10.1164/ajrccm.159.3.9804147 PMID: 10051244
14. Adegbola RA, Hill P, Baldeh I, Otu J, Sarr R, Sillah J, et al (2003) Surveillance of drug-resistant Myco-
bacterium tuberculosis in The Gambia. Int J Tuberc Lung Dis 7:390–393 PMID: 12729346
15. Tudo´ G, Gonza´lez J, Obama R, Rodrı´guez JM, Franco JR, Espasa M et al (2004) Study of resistance to
anti-tuberculosis drugs in five districts of Equatorial Guinea: rates, risk factors, genotyping of gene
mutations and molecular epidemiology. Int J Tuberc Lung Dis 8:15–22 PMID: 14974741
16. Urassa W, Mugusi F, Villamor E, Msamanga G, Moshiro C, Bosch R, et al. (2008) Primary antimicrobial
resistance among Mycobacterium tuberculosis isolates from HIV seropositive and HIV seronegative
patients in Dar es Salaam Tanzania. BMC Res Notes 1:58 https://doi.org/10.1186/1756-0500-1-58
PMID: 18710511
17. Mac-Arthur A, Gloyd S, Perdigão P, Noya A, Sacarlal J, Kreiss J (2001) Characteristics of drug resis-
tance and HIV among tuberculosis patients in Mozambique. Int J Tuberc Lung Dis 5:894–902 PMID:
11605881
18. Diguimbaye C, Hilty M, Ngandolo R, Mahamat HH, Pfyffer GE, Baggi F, et al. (2006) Molecular charac-
terization and drug resistance testing of Mycobacterium tuberculosis isolates from Chad. J Clin Micro-
biol 44:1575–1577 https://doi.org/10.1128/JCM.44.4.1575-1577.2006 PMID: 16597898
MDR-TB trend in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0185105 September 25, 2017 12 / 15
19. Affolabi D, Adjagba OABG, Tanimomo-Kledjo B, Gninafon M, Anagonou SY, Portaels F (2007) Anti-
tuberculosis drug resistance among new and previously treated pulmonary tuberculosis patients in
Cotonou, Benin. Int J Tuberc Lung Dis 11:1221–1224 PMID: 17958985
20. Nunes EA, De Capitani EM, Coelho E, Joaquim OA, Figueiredo IRO, Cossa AM, et al. (2005) Patterns
of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002–2003.
Int J Tuberc Lung Dis 9:494–500 PMID: 15875919
21. Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Britton S, Feleke Y, et al. (2002) Evaluation of outpatients
with suspected pulmonary tuberculosis in a high HIV prevalence setting in Ethiopia: clinical, diagnostic
and epidemiological characteristics. Scand J Infect Dis 34:331–337 PMID: 12069014
22. Nelson LJ, Talbot EA, Mwasekaga MJ, Ngirubiu PK, Mwansa RA, Notha M, et al. (2005) Antituberculo-
sis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet
366:488–490 https://doi.org/10.1016/S0140-6736(05)67062-6 PMID: 16084258
23. Asmamaw D, Seyoum B, Makonnen E, Atsebeha H, Woldemeskel D, Yamuah L, et al. (2008) Primary
drug resistance in newly diagnosed smear positive tuberculosis patients in Addis Ababa, Ethiopia.
Ethiop Med J 46:367–374 PMID: 19271401
24. Owusu-Dabo E, Adjei O, Meyer CG, Horstmann RD, Enimil A, Kruppa TF et al (2006) Mycobacterium
tuberculosis drug resistance, Ghana. Emerging Infect Dis 12:1171–1172 https://doi.org/10.3201/
eid1207.051028 PMID: 16848046
25. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M et al (2010) Emergence of
increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South
Africa. Emerging Infect Dis 16:264–271 https://doi.org/10.3201/eid1602.090968 PMID: 20113557
26. N’guessan K, Dosso M, Nahoua I, Koffi MS, Kouakou J (2008) Primary resistance to antituberculosis
drugs: trends in Cote d’Ivoire from 1995 to 2006. Med Mal Infect 38:231–232 https://doi.org/10.1016/j.
medmal.2007.11.004 PMID: 18262379
27. Chonde TM, Basra D, Mfinanga SGM, Range N, Lwilla F, Shirima RP et al (2010) National anti-tubercu-
losis drug resistance study in Tanzania. Int J Tuberc Lung Dis 14:967–972 PMID: 20626940
28. Mulenga C, Chonde A, Bwalya IC, Kapata N, Kakungu-Simpungwe M, et al. (2010) Low Occurrence of
Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a
Long-Running DOTS Program in Zambia. Tuberc Res Treat 2010:938178 https://doi.org/10.1155/
2010/938178 PMID: 22567261
29. Matee M, Mfinanga S, Holm-Hansen C (2009) Anti-TB drug resistance levels and patterns among
Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es
Salaam, Tanzania. APMIS 117:263–267 https://doi.org/10.1111/j.1600-0463.2008.02429.x PMID:
19338514
30. Gudo PS, Cuna Z, Coelho E, Maungate S, Borroni E, Miotto P, et al (2011) Is MDR-TB on the rise in
Mozambique? Results of a national drug resistance survey. Eur Respir J. 38:222–224 https://doi.org/
10.1183/09031936.00182010 PMID: 21719501
31. Umubyeyi AN, Vandebriel G, Gasana M, et al (2007) Results of a national survey on drug resistance
among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis 11:189–194 PMID:
17263290
32. Ramarokoto H, Ratsirahonana O, Soares JL, Ravaosolo J, Ravololonandriana P, Rakotoarisaonina A
et al (2010) First national survey of Mycobacterium tuberculosis drug resistance, Madagascar, 2005–
2006. Int J Tuberc Lung Dis 14:745–750 PMID: 20487614
33. Asiimwe BB, Ghebremichael S, Kallenius G, Koivula T, Joloba ML (2008) Mycobacterium tuberculosis
spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kam-
pala, Uganda. BMC Infect Dis 8:101 https://doi.org/10.1186/1471-2334-8-101 PMID: 18662405
34. Yimer SA, Agonafir M, Derese Y, Sani Y, Bjune GA, Holm-Hansen C (2012) Primary drug resistance to
anti-tuberculosis drugs in major towns of Amhara region, Ethiopia. APMIS 120:503–509 https://doi.org/
10.1111/j.1600-0463.2011.02861.x PMID: 22583363
35. Lukoye D, Cobelens FGJ, Ezati N, Kirimunda S, Adatu FE, Lule JK, et al. (2011) Rates of anti-tuberculo-
sis drug resistance in Kampala-Uganda are low and not associated with HIV infection. PLoS ONE 6:
e16130 https://doi.org/10.1371/journal.pone.0016130 PMID: 21249225
36. Sanders M, Van Deun A, Ntakirutimana D, Masabo JP, Rukundo J, Rigouts L, et al (2006) Rifampicin
mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey.
Int J Tuberc Lung Dis 10:178–183 PMID: 16499257
37. Kapata N, Chanda-Kapata P, Ngosa W, Metitiri M, Klinkenberg E, Kalisvaart N et al (2016) The Preva-
lence of Tuberculosis in Zambia: Results from the First National TB Prevalence Survey, 2013–2014.
PLoS ONE 11:e0146392 https://doi.org/10.1371/journal.pone.0146392 PMID: 26771588
MDR-TB trend in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0185105 September 25, 2017 13 / 15
38. Bazira J, Asiimwe BB, Joloba ML, Bwanga F, Matee MI (2010) Use of the GenoType(R) MTBDRplus
assay to assess drug resistance of Mycobacterium tuberculosis isolates from patients in rural Uganda.
BMC Clin Pathol 10:5 https://doi.org/10.1186/1472-6890-10-5 PMID: 20691055
39. Pokam BT, Asuquo AE, Abia-Bassey LN, Idasa MB, Umoh NO, Eko FO, et al. (2013) Multidrug resis-
tance and demography of newly diagnosed tuberculosis patients in Cross River State, Nigeria. Int J
Mycobacteriol 2:89–93 https://doi.org/10.1016/j.ijmyco.2013.03.002 PMID: 26785895
40. Minime-Lingoupou F, Manirakiza A, Yango F, Zandanga G, Le Faou A, Rigouts L (2011) Relatively low
primary resistance to anti-tuberculosis drugs in Bangui and Bimbo, Central African Republic. Int J
Tuberc Lung Dis 15:657–661 https://doi.org/10.5588/ijtld.10.0292 PMID: 21756518
41. Diande´ S, Sangare´ L, Kouanda S, Dingoumda BI, Traore´ AS (2009) Drug resistance of Mycobacterium
tuberculosis complex among newly diagnosed tuberculosis cases in Burkina Faso. West Afr J Med
28:353–357 PMID: 20486091
42. Abdelhadi O, Ndokaïn J, Ali MM, Friocourt V, Mortier E, Heym B (2012) [Drug resistance testing of
Mycobacterium tuberculosis isolates from sputum in Chad]. Bull Soc Pathol Exot 105:16–22 https://doi.
org/10.1007/s13149-011-0186-9 PMID: 21960358
43. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC (2012) First- and second-line anti-tuberculosis
drug resistance in Northwest Ethiopia. Int J Tuberc Lung Dis 16:805–811 https://doi.org/10.5588/ijtld.
11.0522 PMID: 22390880
44. Sanchez-Padilla E, Dlamini T, Ascorra A, Ru¨sch-Gerdes S, Tefera ZD, Calain P, et al. (2012) High prev-
alence of multidrug-resistant tuberculosis, Swaziland, 2009–2010. Emerging Infect Dis 18:29–37
https://doi.org/10.3201/eid1801.110850 PMID: 22260950
45. Daniel O, Osman E (2011) Prevalence and risk factors associated with drug resistant TB in South West,
Nigeria. Asian Pac J Trop Med 4:148–151 https://doi.org/10.1016/S1995-7645(11)60057-6 PMID:
21771441
46. Sangare´ L, Diande´ S, Badoum G, Dingtoumda B, Traore´ AS (2010) Anti-tuberculosis drug resistance in
new and previously treated pulmonary tuberculosis cases in Burkina Faso. Int J Tuberc Lung Dis
14:1424–1429 PMID: 20937182
47. Cox HS, McDermid C, Azevedo V, Muller O, Coetzee D, Simpson J, et al. (2010) Epidemic levels of
drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South
Africa. PLoS ONE 5:e13901 https://doi.org/10.1371/journal.pone.0013901 PMID: 21085569
48. Ndung’u PW, Kariuki S, Ng’ang’a Z, Revathi G (2012) Resistance patterns of Mycobacterium tuberculo-
sis isolates from pulmonary tuberculosis patients in Nairobi. J Infect Dev Ctries 6:33–39 PMID:
22240426
49. Abebe G, Abdissa K, Abdissa A, Apers L, Agonafir M, de-Jong BC, et al. (2012) Relatively low primary
drug resistant tuberculosis in southwestern Ethiopia. BMC Res Notes 5:225 https://doi.org/10.1186/
1756-0500-5-225 PMID: 22574696
50. Abouyannis M, Dacombe R, Dambe I, Mpunga J, Faragher B, Gausi F et al (2014) Drug resistance of
Mycobacterium tuberculosis in Malawi: a cross-sectional survey. Bull World Health Organ 92:798–806
https://doi.org/10.2471/BLT.13.126532 PMID: 25378741
51. Aliyu G, El-Kamary SS, Abimiku A‘le, Ezati N, Mosunmola I, Hungerford L, et al. (2013) Mycobacterial
Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in
Northern Nigeria. Tuberc Res Treat 2013:650561 https://doi.org/10.1155/2013/650561 PMID:
23970967
52. Lukoye D, Adatu F, Musisi K, Kasule GW, Were W, Odeke R, et al. (2013) Anti-tuberculosis drug resis-
tance among new and previously treated sputum smear-positive tuberculosis patients in Uganda:
results of the first national survey. PLoS ONE 8:e70763 https://doi.org/10.1371/journal.pone.0070763
PMID: 23936467
53. Drug-Resistant Tuberculosis in Africa. In: PubMed Journals. https://ncbi.nlm.nih.gov/labs/articles/
11795401/. Accessed 27 May 2017
54. Multi-drug resistance tuberculosis (mdr-tb) survey in North East Nigeria. https://www.researchgate.net/
publication/264861293_Multi-drug_resistance_tuberculosis_mdr-tb_survey_in_North_East_Nigeria.
Accessed 27 May 2017
55. Otu A, Umoh V, Habib A, Ameh S, Lawson L, Ansa V (2013) Drug Resistance among Pulmonary Tuber-
culosis Patients in Calabar, Nigeria. Pulm Med 2013:235190 https://doi.org/10.1155/2013/235190
PMID: 24078872
56. Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G (2015) Multidrug resistant tubercu-
losis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. BMC
Infect Dis 15:461 https://doi.org/10.1186/s12879-015-1202-7 PMID: 26503269
MDR-TB trend in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0185105 September 25, 2017 14 / 15
57. The Prevalence of Drug-Resistant Tuberculosis among People Living with HIV (PLHIV) in Abia State.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=67504. Accessed 27 May 2017
58. Sangare´ L, Diande´ S, Oue´draogo G, Traore´ A (2011) HIV Infection and Mycobacterium Tuberculosis
Drug-Resistance among tuberculosis patients in Burkina Faso, West Africa. AFR J CLN EXPER
MICROBIOL 12:38–43
59. Lawson L, Habib AG, Okobi MI, Idiong D, Olajide I, Emenyonu N, et al. (2010) Pilot study on multidrug
resistant tuberculosis in Nigeria. Ann Afr Med 9:184–187 https://doi.org/10.4103/1596-3519.68355
PMID: 20710112
60. South African Tuberculosis Drug Resistance Survey 2012–14. In: NATIONAL INSTITUTE FOR COM-
MUNICABLE DISEASES. http://www.nicd.ac.za/assets/files/K-12750%20NICD%20National%
20Survey%20Report_Dev_V11-LR.pdf. Accessed 27 May 2017
61. Sanchez-Padilla E, Ardizzoni E, Sauvageot D, Ahoua L, Martin A, Varaine F, et al. (2013) Multidrug-
and isoniazid-resistant tuberculosis in three high HIV burden African regions. Int J Tuberc Lung Dis
17:1036–1042 https://doi.org/10.5588/ijtld.12.0842 PMID: 23827027
62. He X, Zhang X, Zhao J, Liu Y, Yu C, Yang G, Li H (2016) Epidemiological Trends of Drug-Resistant
Tuberculosis in China From 2007 to 2014. Medicine (Baltimore).
63. Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM et al (2012) Rise in
rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 16:
196–202 https://doi.org/10.5588/ijtld.11.0116 PMID: 22236920
64. Cohn DL, Bustreo F, Raviglione MC (1997) Drug-resistant tuberculosis: review of the worldwide situa-
tion and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and
Lung Disease. Clin Infect Dis 24 Suppl 1:S121–130
65. Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simulta-
neous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. (2011) World
Health Organization, Geneva
MDR-TB trend in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0185105 September 25, 2017 15 / 15
